In:
Journal of Clinical Microbiology, American Society for Microbiology, Vol. 41, No. 12 ( 2003-12), p. 5781-5782
Kurzfassung:
Recombinant severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein was employed to establish an antigen-capturing enzyme-linked immunosorbent assay (ELISA). Antinucleocapsid protein antibodies could be detected in 68.4% of probable SARS patients 6 to 10 days after illness and in 89.6% of the patients 11 to 61 days after illness. No false-positive results were observed in 20 non-SARS fever patients, 24 non-SARS respiratory illness patients, and 20 health care workers. Among 940 other non-SARS clinical serum samples, only 1 was found to be weakly positive. This method provides a new, sensitive, and specific approach for SARS diagnosis.
Materialart:
Online-Ressource
ISSN:
0095-1137
,
1098-660X
DOI:
10.1128/JCM.41.12.5781-5782.2003
Sprache:
Englisch
Verlag:
American Society for Microbiology
Publikationsdatum:
2003
ZDB Id:
1498353-9
SSG:
12
